Literature DB >> 14500907

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

Celina G Kleer1, Qi Cao, Sooryanarayana Varambally, Ronglai Shen, Ichiro Ota, Scott A Tomlins, Debashis Ghosh, Richard G A B Sewalt, Arie P Otte, Daniel F Hayes, Michael S Sabel, Donna Livant, Stephen J Weiss, Mark A Rubin, Arul M Chinnaiyan.   

Abstract

The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer. Here we investigate the functional role of EZH2 in cancer cell invasion and breast cancer progression. EZH2 transcript and protein were consistently elevated in invasive breast carcinoma compared with normal breast epithelia. Tissue microarray analysis, which included 917 samples from 280 patients, demonstrated that EZH2 protein levels were strongly associated with breast cancer aggressiveness. Overexpression of EZH2 in immortalized human mammary epithelial cell lines promotes anchorage-independent growth and cell invasion. EZH2-mediated cell invasion required an intact SET domain and histone deacetylase activity. This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500907      PMCID: PMC208805          DOI: 10.1073/pnas.1933744100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  Polycomb group protein complexes: do different complexes regulate distinct target genes?

Authors:  D P Satijn; A P Otte
Journal:  Biochim Biophys Acta       Date:  1999-10-06

2.  Do we need prognostic factors in nodal-negative breast cancer? Arbiter.

Authors:  D F Hayes
Journal:  Eur J Cancer       Date:  2000-02       Impact factor: 9.162

3.  Tissue microarray assessment of prostate cancer tumor proliferation in African- American and white men.

Authors:  E E Perrone; C Theoharis; N R Mucci; S Hayasaka; J M Taylor; K A Cooney; M A Rubin
Journal:  J Natl Cancer Inst       Date:  2000-06-07       Impact factor: 13.506

Review 4.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

5.  Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.

Authors:  J J Jacobs; B Scheijen; J W Voncken; K Kieboom; A Berns; M van Lohuizen
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

6.  Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma.

Authors:  D L Livant; R K Brabec; K J Pienta; D L Allen; K Kurachi; S Markwart; A Upadhyaya
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

7.  Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease.

Authors:  F M Raaphorst; F J van Kemenade; T Blokzijl; E Fieret; K M Hamer; D P Satijn; A P Otte; C J Meijer
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

8.  Validation of tissue microarray technology in breast carcinoma.

Authors:  R L Camp; L A Charette; D L Rimm
Journal:  Lab Invest       Date:  2000-12       Impact factor: 5.662

9.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

10.  Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.

Authors:  L Huang; A B Pardee
Journal:  Mol Med       Date:  2000-10       Impact factor: 6.354

View more
  709 in total

Review 1.  Functional Crosstalk Between Lysine Methyltransferases on Histone Substrates: The Case of G9A/GLP and Polycomb Repressive Complex 2.

Authors:  Chiara Mozzetta; Julien Pontis; Slimane Ait-Si-Ali
Journal:  Antioxid Redox Signal       Date:  2014-12-19       Impact factor: 8.401

2.  Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma.

Authors:  Cheng Wang; Xiqiang Liu; Zujian Chen; Hongzhang Huang; Yi Jin; Antonia Kolokythas; Anxun Wang; Yang Dai; David T W Wong; Xiaofeng Zhou
Journal:  Mol Carcinog       Date:  2011-12-07       Impact factor: 4.784

3.  Characterization of KRAS rearrangements in metastatic prostate cancer.

Authors:  Xiao-Song Wang; Sunita Shankar; Saravana M Dhanasekaran; Bushra Ateeq; Atsuo T Sasaki; Xiaojun Jing; Daniel Robinson; Qi Cao; John R Prensner; Anastasia K Yocum; Rui Wang; Daniel F Fries; Bo Han; Irfan A Asangani; Xuhong Cao; Yong Li; Gilbert S Omenn; Dorothee Pflueger; Anuradha Gopalan; Victor E Reuter; Emily Rose Kahoud; Lewis C Cantley; Mark A Rubin; Nallasivam Palanisamy; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

4.  Regulation of DU145 prostate cancer cell growth by Scm-like with four mbt domains 2.

Authors:  Kwanghyun Lee; Wonho Na; Je-Heon Maeng; Hongjin Wu; Bong-Gun Ju
Journal:  J Biosci       Date:  2013-03       Impact factor: 1.826

5.  Histone demethylase RBP2 is critical for breast cancer progression and metastasis.

Authors:  Jian Cao; Zongzhi Liu; William K C Cheung; Minghui Zhao; Sophia Y Chen; Siew Wee Chan; Carmen J Booth; Don X Nguyen; Qin Yan
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

Review 6.  Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Authors:  Bayley A Jones; Sooryanarayana Varambally; Rebecca C Arend
Journal:  Mol Cancer Ther       Date:  2018-03       Impact factor: 6.261

7.  KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.

Authors:  Alexandros Tzatsos; Polina Paskaleva; Francesco Ferrari; Vikram Deshpande; Svetlana Stoykova; Gianmarco Contino; Kwok-Kin Wong; Fei Lan; Patrick Trojer; Peter J Park; Nabeel Bardeesy
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

Review 8.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

Review 9.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

10.  Role of transcriptional corepressor CtBP1 in prostate cancer progression.

Authors:  Rui Wang; Irfan A Asangani; Balabhadrapatruni V S K Chakravarthi; Bushra Ateeq; Robert J Lonigro; Qi Cao; Ram-Shankar Mani; Daniel F Camacho; Natalie McGregor; Taibriana E W Schumann; Xiaojun Jing; Radhika Menawat; Scott A Tomlins; Heng Zheng; Arie P Otte; Rohit Mehra; Javed Siddiqui; Saravana M Dhanasekaran; Mukesh K Nyati; Kenneth J Pienta; Nallasivam Palanisamy; Lakshmi P Kunju; Mark A Rubin; Arul M Chinnaiyan; Sooryanarayana Varambally
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.